These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30546081)

  • 1. Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
    Scherr M; Kirchhoff H; Battmer K; Wohlan K; Lee CW; Ricke-Hoch M; Erschow S; Law E; Kloos A; Heuser M; Ganser A; Hilfiker-Kleiner D; Heidenreich O; Eder M
    Leukemia; 2019 Jun; 33(6):1313-1323. PubMed ID: 30546081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
    Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
    Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
    Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
    J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Nguyen T; Dai Y; Attkisson E; Kramer L; Jordan N; Nguyen N; Kolluri N; Muschen M; Grant S
    Clin Cancer Res; 2011 May; 17(10):3219-32. PubMed ID: 21474579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.
    Alvarez-Calderon F; Gregory MA; Pham-Danis C; DeRyckere D; Stevens BM; Zaberezhnyy V; Hill AA; Gemta L; Kumar A; Kumar V; Wempe MF; Pollyea DA; Jordan CT; Serkova NJ; Graham DK; DeGregori J
    Clin Cancer Res; 2015 Mar; 21(6):1360-72. PubMed ID: 25547679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
    Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
    J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
    Heaney NB; Pellicano F; Zhang B; Crawford L; Chu S; Kazmi SM; Allan EK; Jorgensen HG; Irvine AE; Bhatia R; Holyoake TL
    Blood; 2010 Mar; 115(11):2241-50. PubMed ID: 20068223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
    Maletzke S; Salimi A; Vieri M; Schroeder KM; Schemionek M; Masouleh BK; Brümmendorf TH; Koschmieder S; Appelmann I
    PLoS One; 2022; 17(10):e0268352. PubMed ID: 36194587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.
    Constance JE; Woessner DW; Matissek KJ; Mossalam M; Lim CS
    Mol Pharm; 2012 Nov; 9(11):3318-29. PubMed ID: 22957899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL
    Budhraja A; Turnis ME; Churchman ML; Kothari A; Yang X; Xu H; Kaminska E; Panetta JC; Finkelstein D; Mullighan CG; Opferman JT
    Clin Cancer Res; 2017 Dec; 23(24):7558-7568. PubMed ID: 28974549
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.
    Kirchhoff H; Karsli U; Schoenherr C; Battmer K; Erschow S; Talbot SR; Steinemann D; Heuser M; Heidenreich O; Hilfiker-Kleiner D; Ganser A; Eder M; Scherr M
    Blood; 2021 May; 137(19):2657-2661. PubMed ID: 33512436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
    Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
    Willmann M; Sadovnik I; Eisenwort G; Entner M; Bernthaler T; Stefanzl G; Hadzijusufovic E; Berger D; Herrmann H; Hoermann G; Valent P; Rülicke T
    Exp Hematol; 2018 Jan; 57():50-59.e6. PubMed ID: 29031704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
    Ultimo S; Simioni C; Martelli AM; Zauli G; Evangelisti C; Celeghini C; McCubrey JA; Marisi G; Ulivi P; Capitani S; Neri LM
    Oncotarget; 2017 Apr; 8(14):23213-23227. PubMed ID: 28390196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.